Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $2,524 | 5 | 68.6% |
| Travel and Lodging | $711.60 | 2 | 19.4% |
| Food and Beverage | $441.76 | 1 | 12.0% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| H. Lundbeck A S | $1,644 | 3 | $0 (2018) |
| PFIZER INC. | $1,153 | 3 | $0 (2019) |
| Allergan Inc. | $880.60 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $2,034 | 5 | PFIZER INC. ($1,153) |
| 2018 | $1,644 | 3 | H. Lundbeck A S ($1,644) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/12/2019 | Allergan Inc. | VRAYLAR (Drug) | — | In-kind items and services | $858.55 | Research |
| Study: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment • Category: NEUROSCIENCE | ||||||
| 04/12/2019 | Allergan Inc. | VRAYLAR (Drug) | — | In-kind items and services | $22.05 | Research |
| Study: A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment • Category: NEUROSCIENCE | ||||||
| 03/11/2019 | PFIZER INC. | GEODON (Drug) | Food and Beverage | In-kind items and services | $441.76 | General |
| Category: NEUROSCIENCE | ||||||
| 03/11/2019 | PFIZER INC. | GEODON (Drug) | Travel and Lodging | In-kind items and services | $423.18 | General |
| Category: NEUROSCIENCE | ||||||
| 03/11/2019 | PFIZER INC. | GEODON (Drug) | Travel and Lodging | In-kind items and services | $288.42 | General |
| Category: NEUROSCIENCE | ||||||
| 11/07/2018 | H. Lundbeck A S | TRINTELLIX (Drug) | — | Cash or cash equivalent | $1,073.21 | Research |
| Study: Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder MDD From 7 to 18 Years of Age • Category: PSYCHIATRY | ||||||
| 11/07/2018 | H. Lundbeck A S | TRINTELLIX (Drug) | — | Cash or cash equivalent | $319.31 | Research |
| Study: Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder MDD From 7 to 18 Years of Age • Category: PSYCHIATRY | ||||||
| 11/07/2018 | H. Lundbeck A S | TRINTELLIX (Drug) | — | Cash or cash equivalent | $251.00 | Research |
| Study: Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder MDD From 7 to 18 Years of Age • Category: PSYCHIATRY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder MDD From 7 to 18 Years of Age | H. Lundbeck A S | $1,644 | 3 |
| A 6-week, International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in the Treatment | Allergan Inc. | $880.60 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 1 | 11 | 33 | $6,369 | $2,545 |
All Medicare Procedures & Services
1 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 33 | $6,369 | $2,545 | 40.0% |
About Dr. Luis Patino Duran, M.D
Dr. Luis Patino Duran, M.D is a Child & Adolescent Psychiatry healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/05/2013. The National Provider Identifier (NPI) number assigned to this provider is 1780923169.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Luis Patino Duran, M.D has received a total of $3,677 in payments from pharmaceutical and medical device companies, with $2,034 received in 2019. These payments were reported across 8 transactions from 3 companies. The most common payment nature is "" ($2,524).
As a Medicare-enrolled provider, Patino Duran has provided services to 11 Medicare beneficiaries, totaling 33 services with total Medicare billing of $2,545. Data is available for 1 year (2021–2021), covering 1 distinct procedure/service records.
Practice Information
- Specialty Child & Adolescent Psychiatry
- Location Cincinnati, OH
- Active Since 02/05/2013
- Last Updated 02/07/2018
- Taxonomy Code 2084P0804X
- Entity Type Individual
- NPI Number 1780923169
Products in Payments
- TRINTELLIX (Drug) $1,644
- GEODON (Drug) $1,153
- VRAYLAR (Drug) $880.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Child & Adolescent Psychiatry Doctors in Cincinnati
Ethan Musgrave, M.d, M.D
Child & Adolescent Psychiatry — Payments: $4,205
Dr. Hilton Rodriguez, M.d, M.D
Child & Adolescent Psychiatry — Payments: $1,064
Dr. Stephen Beck, M.d, M.D
Child & Adolescent Psychiatry — Payments: $440.17
Susan Merwin, Md, MD
Child & Adolescent Psychiatry — Payments: $403.67
Mark Johnson, M.d, M.D
Child & Adolescent Psychiatry — Payments: $357.75
Jacqueline Janecek, M.d, M.D
Child & Adolescent Psychiatry — Payments: $298.57